Solasia Pharma K.K.
4597.T News Today: Stay Updated with the Latest Solasia Pharma K.K. News in Real Time
Find 4597.T news now at Meyka AI. Stay informed with the latest Solasia Pharma K.K. stocks updates, including price news, market analysis, and expert insights.
NSRX Insider Trade: Rubin Eyal CFO Share Options Filing May 2026
Nasus Pharma CFO Rubin Eyal files initial ownership of 40,549 share options worth $306,550. Form 3 filing reveals executive compensation structure.
IDIA.SW stock surges 6.9% on May 7, 2026 amid biotech momentum
IDIA.SW stock jumps 6.9% to CHF 3.978 on SIX exchange. Idorsia Ltd biotech gains momentum with strong volume activity.
OPHLY Earnings Preview: Ono Pharma Reports May 8, 2026
Ono Pharmaceutical earnings preview for May 8, 2026. EPS estimate $0.0172, revenue estimate $717.88M. Meyka AI rates OPHLY B+.
Kühne+Nagel Stock May 7: Pharma Hub Expansion in India
Kühne+Nagel opens temperature-controlled pharma hub in Hyderabad to expand healthcare logistics and specialized medical transport in India.
Zealand Pharma Jumps 12% After Q1 Revenue Beat and DKK 1.3B Buyback
Zealand Pharma shares surged around 12% after the company reported better than expected Q1 revenue and announced a large share buyback program worth DKK 1.3 billion. The strong performance reflected investor confidence in the company’s growth outlook and its expanding pipeline in metabolic and rare disease treatments. The rally in Zealand Pharma also attracted attention…
4551.T Stock Bounces 0.32% After Oversold Pullback on JPX
Torii Pharmaceutical (4551.T) shows oversold bounce signals with strong fundamentals, zero debt, and Meyka AI grade B rating on JPX.
Bayer Stock May 7: $2.45B Perfuse Deal Signals Pharma Shift
Bayer acquires Perfuse Therapeutics for $2.45B to strengthen ophthalmology pipeline with PER-001 eye implant candidate.
Bayer Stock May 7: $2.45B Perfuse Deal Signals Pharma Shift
Bayer acquires Perfuse Therapeutics for $2.45B to strengthen ophthalmology portfolio with PER-001 drug candidate, addressing Eylea patent risks.
TGTX: H.C. Wainwright Maintains Buy Rating, May 2026
H.C. Wainwright maintains Buy rating on TGTX, raising price target to $70 from $60. Stock up 16.26% on strong earnings.